Evidence map›Paper›PMID 38895380›Full record

ArticlebioRxiv : the preprint server for biology2024

TYK2 as a novel therapeutic target in Alzheimer's Disease with TDP-43 inclusions.

Laura E König, Steve Rodriguez, Clemens Hug, Shayda Daneshvari, Alexander Chung, Gary A Bradshaw, Asli Sahin, George Zhou, Robyn J Eisert, Federica Piccioni and 6 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Laura E KönigLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Armenise 132, 200 Longwood Avenue, Boston, MA 02115, USA.
Steve RodriguezLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Armenise 132, 200 Longwood Avenue, Boston, MA 02115, USA.
Clemens HugLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Armenise 132, 200 Longwood Avenue, Boston, MA 02115, USA.
Shayda DaneshvariLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Armenise 132, 200 Longwood Avenue, Boston, MA 02115, USA.
Alexander ChungLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Armenise 132, 200 Longwood Avenue, Boston, MA 02115, USA.
Gary A BradshawLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Armenise 132, 200 Longwood Avenue, Boston, MA 02115, USA.
Asli SahinDepartment of Neurology, Massachusetts General Hospital, 114 16 Street, Charlestown, MA 02129, USA.
George ZhouDepartment of Neurology, Massachusetts General Hospital, 114 16 Street, Charlestown, MA 02129, USA.
Robyn J EisertLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Armenise 132, 200 Longwood Avenue, Boston, MA 02115, USA.
Federica PiccioniBroad Institute of MIT and Harvard, 75 Ames Street, Cambridge, MA 02142, USA.
Sudeshna DasDepartment of Neurology, Massachusetts General Hospital, 114 16 Street, Charlestown, MA 02129, USA.
Marian KalocsayLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Armenise 132, 200 Longwood Avenue, Boston, MA 02115, USA.
Artem SokolovLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Armenise 132, 200 Longwood Avenue, Boston, MA 02115, USA.
Peter SorgerLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Armenise 132, 200 Longwood Avenue, Boston, MA 02115, USA.
David E RootBroad Institute of MIT and Harvard, 75 Ames Street, Cambridge, MA 02142, USA.
Mark W AlbersLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Armenise 132, 200 Longwood Avenue, Boston, MA 02115, USA.

Funding

Systems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule DrugsU54CA225088 · NCI · HARVARD MEDICAL SCHOOL · PI HAIGIS, MARCIA · 2018 to 2022
$10.8M
Harnessing Diverse Bioinformatic Approaches To Repurpose Drugs For Alzheimers Disease And Related DementiasR01AG058063 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI MARK W ALBERS, PETER Karl SORGER · 2018 to 2026
$7.8M
Defining the pathogenic relationship of TDP-43 inclusions and cytoplasmic double stranded RNA in AD and FTDR01AG078377 · NIA · HARVARD MEDICAL SCHOOL · PI MARK W ALBERS · 2025 to 2026
$1.6M
NCI NIH HHS U54 CA225088NIA NIH HHS R01 AG058063NIA NIH HHS R01 AG078377
6 · The paper itself

Abstract

Neuroinflammation is a pathological feature of many neurodegenerative diseases, including Alzheimer's disease (AD)

Identifiers

PMID38895380
PMCPMC11185596

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.